Kyntra Bio, Inc.
KYNB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000921299
No open-market purchases or sales by Kyntra Bio, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $7.54M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $14.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −4 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $7.54M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $6.44M
- −78.3% year over year
- Net income, FY2025
- $183.5M
- No comparable prior period
- Free cash flow, FY2025
- -$4.81M
- No comparable prior period
- Revenue, Q2 FY2026
- -$1.47M
- −209.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net income for FY2025: $183.5M (2848.6% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 95.8K
- Shares sold short
- Change
- +827
- +0.9% vs. previous
- Days to cover
- 4.68
- At average daily volume
Superinvestors holding KYNB, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KYNB at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Kyntra Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 (view filing) | May 14 | 5 days | Wettig ThaneCEO | PPurchase | +2.80K | $7.09 | +$19.9K | +11.5%27.2K after | Amended |
| Nov 17, 2025 (view filing) | Nov 13-17 | 4 days | Wettig ThaneCEO | PPurchase | +3.70K | $9.12 | +$33.8K | +17.4%24.9K after | 2 lots |
| Jul 2, 2025 (view filing) | Jun 30 | 2 days | Schoeneck James ADirector | PPurchase | +23.6K | $5.07 | +$119.5K | +146.4%39.7K after | |
| Mar 25, 2025 (view filing)9:00 AM ET | Mar 24 | 1 day | Wettig ThaneCEO | PPurchase | +145.0K | $0.3494 | +$50.7K | +36.4%543.3K after | |
| Mar 24, 2025 (view filing)9:00 AM ET | Mar 20-21 | 4 days | Schoeneck James ADirector | PPurchase | +300.0K | $0.3501 | +$105.0K | +406.9%373.7K after | 2 lots |
| Jun 13, 2024 (view filing) | Jun 12 | 1 day | Adib DeyaaChief Medical Officer | PPurchase | +22.1K | $1.17 | +$25.9K | +36.9%82.1K after | |
| Mar 11, 2024 (view filing) | Mar 7 | 4 days | Wettig ThaneCEO | PPurchase | +50.0K | $1.91 | +$95.5K | +11.9%470.2K after | |
| Sep 6, 2023 (view filing) | Sep 1 | 5 days | Henderson Jeffrey WilliamDirector | SSale | −2.00K | $1.03 | −$2.06K | −6.5%28.9K after | 10b5-1 |
| Aug 8, 2023 (view filing) | Aug 4 | 4 days | Henderson Jeffrey WilliamDirector | SSale | −2.00K | $1.91 | −$3.82K | −6.1%30.9K after | 10b5-1 |
| Jul 13, 2023 (view filing) | Jul 11 | 2 days | Henderson Jeffrey WilliamDirector | SSale | −2.00K | $2.69 | −$5.38K | −5.7%32.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 27 holdersThe largest institutional positions in Kyntra Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 400,000 | $3.02M | 0.08% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 159,950 | $1.21M | 0.00% | +3,343+2.1% | Added |
| Acadian Asset Management LLC | 105,585 | $795.0K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 84,330 | $636.7K | 0.00% | −10.0% | Reduced |
| Geode Capital Management, LLC | 43,219 | $326.4K | 0.00% | −2,779−6.0% | Reduced |
| HighTower Advisors, LLC | 39,746 | $300.1K | 0.00% | +20.0% | Added |
| Two Sigma Investments, LP | 39,511 | $298.3K | 0.00% | −10,000−20.2% | Reduced |
| Renaissance Technologies LLC | 27,081 | $204.5K | 0.00% | −400−1.5% | Reduced |
| Vanguard Fiduciary Trust Co | 24,105 | $182.0K | 0.00% | +163+0.7% | Added |
| Birchview Capital, LP | 22,566 | $170.4K | 0.08% | 00.0% | Unchanged |
Holders of 5% or more of KYNB
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Kyntra Bio, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 13G/A | 9.88%400.0K shares | 0.00 ppfrom 9.88% | Feb 14, 20249 filings | Aug 14, 2026 | SEC |